Karen Malone

Dr. Karen Malone

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
TLTarik Luisman
Tarik Luisman
TSTara Smith
Tara Smith
SRShawn Ritchie
Shawn Ritchie
KMKaren Malone
Karen Malone
Background: Rhizomelic chondrodysplasia punctata (RCDP) is an inherited ultra-rare disease which results in severely impaired physical and mental development. Mutations in one of five genes involved in plasmalogen biosynthesis have been reported to drive disease pathology. Estimates of disease incidence have been extremely challenging due to the rarity of the disorder, preventing an understanding of the unmet medical need. To address this, we have prepared a disease incidence and prevalence model based on genetic epidemiology approaches to estimate the total number of RCDP patients affected, and their demographic characteristics. Results: Extraction of allelic frequencies for known and predicted pathogenic variants in PEX7, GNPAT, AGPS, FAR1, PEX5 (limited to the PTS2 domain encoding region) genes, from large-scale human genetic diversity datasets (TopMed and gnomAD) revealed the mutational landscape contributing to the RCDP patient population in the US and Europe. We computed genetic prevalence to derive birth incidence for RCDP and modeled the impact to life expectancy to obtain high confidence estimates of disease prevalence. Our population genetics-based model indicates PEX7 variants are expected to contribute to the majority of RCDP cases in both the US and Europe; closely aligning with clinical reports. Furthermore, this model provides estimates for RCDP subtypes due to mutations in other genes, including exceedingly rare subtypes. Conclusion: In total, the estimated number of RCDP patients in the US and the five largest European countries (UK, Germany, France, Italy and Spain) is between 516 and 847 patients, all under the age of 35 years old. This model provides a quantitative framework for better understanding the unmet medical need in RCDP, to help guide disease awareness and diagnosis efforts for this specific patient group.

14 September 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
MLMatthijs Leenders
Matthijs Leenders
MGMathijs Gaastra
Mathijs Gaastra
AJAsh Jayagopal
Ash Jayagopal
KMKaren Malone
Karen Malone

2 September 2024 in Research Square
Verified
Preprint
Open access
PDF file
KMKatarina Mueller
Katarina Mueller
MSMary Grace Shine
Mary Grace Shine
JLJae Lee
Jae Lee
SLSoo-Kyung Lee
Soo-Kyung Lee
KMKaren Malone
Karen Malone
Background and Objectives FOXG1 Syndrome was first identified in 2005 and has been closely associated with Rett Syndrome. However, with access to genetic testing an increasing number of patients have been identified that do not fulfill Rett Syndrome clinical criteria. Utilizing genetic surveys of large, severe neurodevelopmental disease (NDD) cohorts, we provide the first prevalence estimates of FOXG1 Syndrome independent of Rett Syndrome clinical criteria. Methods We performed a systematic review and meta-analysis of studies conducting extensive genetic testing on cohorts of severe neurodevelopmental patients within the last ten years. Fourteen studies were included, after exclusion of outliers biased for FOXG1 patients, providing analysis of over 36,000 severe neurodevelopmental disease pediatric patients in total. Results FOXG1 patients accounted for 0.20% [95% CI: 0.15–0.25%] of severe NDD pediatric patients. MECP2 and CDKL5 patients accounted for 0.54% [95% CI: 0.47–0.62%] and 0.35% [95% CI: 0.29–0.41%], respectively. This results in an estimated prevalence of 0.6–2.2 FOXG1 patients per 100,000 children or ~ 430–1600 patients in the United States. The estimated prevalence of CDLK5 patients was 2.1–7.7 cases per 100,000 female children, and the estimated prevalence of MECP2 patients was 3.2–11.9 cases per 100,000 female children. Conclusions Estimated prevalence of MECP2-driven severe NDD was comparable to estimates based on Rett Syndrome clinical criteria. Similarly, CDKL5-driven NDD were also comparable to an earlier study. However, prevalence estimates for FOXG1-associated severe NDD were ~ 10 times higher than expected if limited to reports based on Rett Syndrome clinical criteria. This data further supports that both FOXG1 Syndrome and CDKL5 deficiency represent distinct and sizable patient populations as compared to MECP2-associated Rett Syndrome. These findings have immediate implications for improved diagnosis of these patients and highlight the benefits of genetic testing in identifying them.

23 April 2025 in Genetics in Medicine Open
Verified
Journal Article
Open access
KMKaren Malone
Karen Malone
CACatherine Argyriou
Catherine Argyriou
EZEvelyn Zavacky
Evelyn Zavacky
nancy bravermannancy braverman
nancy braverman
Zellweger Spectrum Disorder (ZSD) is a rare syndromic disorder characterized by impaired peroxisome assembly and function. Many cases are due to pathogenic variants in the PEX1 gene and are inherited in an autosomal recessive manner. As with many rare diseases, understanding the disease burden and scale of unmet need is challenging but required to support diagnosis, disease management, and development of therapies. We present a population-genetics-based model to estimate births and overall disease prevalence for patients in the United States, European countries, and Japan. We utilized large-scale genetic diversity data sets to estimate the mutational burden per region and integrated genotype-phenotype relationships with real-world survival data to provide patient number estimates for severe, intermediate, and mild segments per age and country. We observed regional differences in the variant landscapes expected to contribute to PEX1-mediated ZSD (PEX1-ZSD). Conservative prevalence estimates for the United States, United Kingdom, Germany, France, Italy, Spain, and Japan based solely on known pathogenic variants indicates nearly 500 patients in total. Incorporating predicted pathogenic variants into our model suggests an additional 260 patients with intermediate phenotype and 930 patients with mild phenotype, under the age of 30, across these countries. Notably, our model indicates that a significant proportion of patients with intermediate/mild phenotype may go unrecognized by current diagnostic practices. This diagnosis independent model of patient number estimates provides additional insights into the broad spectrum of PEX1-ZSD on a more global scale and can be used to inform health care strategies for these patients.

16 September 2026 in BMJ Connections Clinical Genetics and Genomics
Verified
Journal Article
Open access
PDF file
MLMatthijs Leenders
Matthijs Leenders
MGMathijs Gaastra
Mathijs Gaastra
STSarah Tuller
Sarah Tuller
GMGeorge Magrath
George Magrath
AJAsh Jayagopal
Ash Jayagopal
KMKaren Malone
Karen Malone
PURPOSEBEST1-associated inherited retinal disease constitutes one of the largest inherited retinal disease patient populations across the world. Innovative therapies are currently in development to address this significant unmet need. To better understand the scale of unmet need, and the distribution of phenotypes and genotypes, we conducted a meta-analysis of BEST1 patients reported in the literature to provide up-to-date patient number estimates. We used the GeneScape IRD Patient Atlas , an expertly curated database of ~73K retinal disease patients undergoing extensive genetic testing, in combination with a dedicated literature search to estimate the proportion of inherited retinal dystrophy (IRD) patients attributed to BEST1 using fixed effects weighting. This was also translated to patient number estimates for each country. Further extrapolation of patient subtypes was estimated based on cohorts of BEST1 patients reporting phenotypes and genotypes. In addition, a summary of contributing variants is reported by region. Across all studied regions, BEST1 retinopathy affects an estimated 24,000 patients, with prevalence varying nearly tenfold between regions: from 1 in 38,000 in Germany to 1 in 363,000 in Japan, though estimates for China carry considerable uncertainty. In western countries, biallelic patients are expected to contribute nearly 20% of the total BEST1 population, whereas one third of patients in East Asia are anticipated to be biallelic. While patients are reported across the world, their prevalence and composition vary across geographies. In the literature, biallelic patients are less often reported explicitly as autosomal recessive Best patients in the USA as compared with Europe. Variant diversity in BEST1 patients is reflected in regional reports and drives phenotypic distribution.

16 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MLMatthijs Leenders
Matthijs Leenders
MGMathijs Gaastra
Mathijs Gaastra
STSarah Tuller
Sarah Tuller
GMGeorge Magrath
George Magrath
AJAsh Jayagopal
Ash Jayagopal
KMKaren Malone
Karen Malone
PURPOSE: BEST1-associated inherited retinal disease constitutes one of the largest inherited retinal disease patient populations across the world. Innovative therapies are currently in development to address this significant unmet need. To better understand the scale of unmet need, and the distribution of phenotypes and genotypes, we conducted a meta-analysis of BEST1 patients reported in the literature to provide up-to-date patient number estimates. METHODS: We utilized the GeneScape IRD Patient Atlas, an expertly curated database of ~73K retinal disease patients undergoing extensive genetic testing, in combination with a dedicated literature search to estimate the proportion of IRD patients attributed to BEST1 using fixed effects weighting. This was also translated to patient number estimates for each country. Further extrapolation of patient subtypes was estimated based on cohorts of BEST1 patients reporting phenotypes and genotypes. In addition, a summary of contributing variants is reported by region. RESULTS: Across regions BEST1 retinopathy patients are estimated to occur from 1 in 38K (in Germany) to 1 in 363K in Japan. In the western countries, bi-allelic patients are expected to contribute nearly 20% of the total BEST1 population, whereas one third of patients in East Asia are anticipated to be bi-allelic. CONCLUSIONS: While patients are reported across the world, their prevalence and composition vary across geographies. In the literature bi-allelic patients are less often reported explicitly as ARB patients in the United States as compared to Europe. Variant diversity is reflected in regional reports and drives phenotypic distribution.